In an older adult with a history of hyponatremia, does bupropion increase anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bupropion Does Not Significantly Increase Anxiety in Most Patients, Including Older Adults with Hyponatremia History

Bupropion is generally safe regarding anxiety symptoms and may even reduce anxiety in patients with depression, though it should be initiated at low doses in older adults with a history of hyponatremia, with close monitoring for both anxiety and sodium levels.

Evidence on Bupropion and Anxiety

The most recent high-quality evidence demonstrates that bupropion does not worsen anxiety in most clinical scenarios. A 2025 systematic review found that bupropion was generally associated with improvements in anxiety symptoms in patients with major depressive disorder, with no clear signal of anxiety worsening on validated anxiety measures 1. While SSRIs showed a modest advantage in patients with high baseline anxiety, individual studies found no significant differences in most presentations 1.

Earlier comparative data supports this: a 2001 meta-analysis showed no difference between bupropion and SSRIs on Hamilton Rating Scale for Anxiety measurements (absolute weighted mean difference 0.37,95% CI -0.85 to 1.6) 2. A 2016 review similarly concluded that bupropion and SSRIs have comparable anxiolytic efficacy in mild to moderate anxiety, though SSRIs may be preferable for severe depression with anxious distress 3.

Clinical Guidelines on Bupropion Use

Multiple guidelines characterize bupropion as "activating" but do not contraindicate its use based on anxiety alone:

  • The 2002 Alzheimer's guidelines note bupropion is "activating" and "should not be used in agitated patients," but distinguish agitation from anxiety 4
  • The 2016 NCCN smoking cessation guidelines found no significant increase in neuropsychiatric adverse events (including anxiety) with bupropion versus placebo in a large multicenter RCT 5
  • The 2022 AGA obesity guidelines reported anxiety occurred in 0.6%-5.4% with naltrexone-bupropion versus 0.2%-4.3% with placebo—no significant difference 6

The key distinction: bupropion should be avoided in patients with severe agitation or acute anxiety states, but is not contraindicated for patients with comorbid anxiety symptoms in the context of depression.

Special Considerations for Older Adults with Hyponatremia History

Your specific clinical scenario requires addressing two concerns:

Hyponatremia Risk

While SSRIs, SNRIs, and mirtazapine are most commonly implicated in antidepressant-induced hyponatremia in older adults 7, bupropion can also cause hyponatremia, though less frequently. A 2016 case report documented bupropion-induced hyponatremia in a 72-year-old woman 8, and a 2025 network meta-analysis found that while venlafaxine, paroxetine, sertraline, citalopram, escitalopram, fluoxetine, and mirtazapine all significantly increased hyponatremia risk, bupropion was not among the agents with established increased risk 9.

Practical approach:

  • Check baseline sodium before initiating bupropion
  • Recheck sodium within 2 weeks of starting treatment 8
  • Monitor for unexplained mental status changes at any time during treatment
  • Consider bupropion may be a safer option than SSRIs/SNRIs in patients with prior hyponatremia 7

Dosing Strategy in Older Adults

The FDA label and clinical guidelines recommend caution in older adults:

  • Start with the lowest available dose (37.5 mg daily initially) 4
  • Increase by 37.5 mg increments every 3-5 days as tolerated 4
  • Maximum dose 150 mg twice daily (give second dose before 3 PM to minimize insomnia) 4
  • Older adults may have increased sensitivity to CNS effects and are more likely to have decreased renal function requiring dose adjustment 10

Common Pitfalls to Avoid

  1. Confusing "activating" with "anxiogenic": Bupropion's activating properties (increased energy, reduced apathy) are distinct from causing anxiety. The activation can be therapeutic for depression with low energy 4.

  2. Starting at full dose: This increases risk of insomnia and overstimulation. Always start low and titrate slowly in older adults 4.

  3. Ignoring timing of second dose: Giving the second dose after 3 PM increases insomnia risk, which can be misinterpreted as anxiety 4.

  4. Failing to monitor sodium: Even though bupropion has lower hyponatremia risk than SSRIs, it can still occur, especially in older adults with prior episodes 8.

  5. Not distinguishing baseline anxiety severity: Patients with severe, high-baseline anxiety may benefit more from SSRIs, while those with mild-moderate anxiety and depression do equally well with bupropion 1, 3.

Monitoring Plan

  • Week 0: Baseline sodium, blood pressure, assess anxiety severity
  • Week 2: Recheck sodium, assess for anxiety symptoms, insomnia, or overstimulation
  • Weeks 4-8: Continue monitoring anxiety and depressive symptoms; full therapeutic trial requires 4-8 weeks 4
  • Ongoing: Monitor for unexplained mental status changes that could indicate hyponatremia 8

References

3
Research

Bupropion and Anxiety: A Brief Review.

Human psychopharmacology, 2025

5
Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

7
Research

Antidepressant-Induced Hyponatremia in Older Adults.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2016

9
Research

Treatment with antidepressant drugs and hyponatremia: a network meta-analysis.

Journal of endocrinological investigation, 2025

Related Questions

For a female patient with depression currently taking bupropion 150 mg, who has experienced emotional blunting from multiple SSRIs and now has OCD‑like intrusive thoughts and situational anxiety, what PRN (as‑needed) pharmacologic options are appropriate that avoid SSRIs?
What is the appropriate initiation, titration, and monitoring plan for bupropion maintenance therapy in a 27-year-old woman with mixed anxiety and depressive disorder?
In a 23-year-old male with anxiety and depression who smokes and wishes to quit, is bupropion (Wellbutrin) an appropriate treatment choice?
A 40-year-old female with a history of depression and anxiety is currently taking Wellbutrin (bupropion) XL 300 mg once daily, Buspar (buspirone) 15 mg twice daily, and sertraline 50 mg once daily. What medication recommendations are appropriate?
In a 59-year-old female nursing-home resident with depression, anxiety, and a history of alcohol abuse who is taking bupropion XL (bupropion) 300 mg daily, escitalopram 20 mg daily, trazodone 100 mg at bedtime and 25 mg in the morning, amphetamine/dextroamphetamine (Adderall) 10 mg daily, and divalproex sodium (Depakote) 250 mg twice daily, and who now presents with worsening depression, social isolation, increased daytime sleepiness, and anhedonia, what is the optimal psychotropic treatment approach?
What hardware is typically used for a distal thumb phalanx arthrodesis?
What is the appropriate outpatient dosing for promethazine (Phenergan) in adults and children?
What are the recent evidence‑based updates in nephrology for managing chronic kidney disease, anemia, hyperkalemia, acute kidney injury, dialysis initiation, home dialysis, and kidney transplantation?
At what age does routine Pap smear screening end, and does STI screening for Chlamydia and Gonorrhea discontinue at that same age?
What is the appropriate treatment for a patient with allergic rhinitis who now presents with nasal congestion, cough, and wheezing?
What does a 20% eosinophilia with mildly elevated alpha‑fetoprotein (9 ng/mL, reference ≤7) and neuron‑specific enolase (20.3 ng/mL, reference ≤18.3) indicate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.